18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

N/ANot Yet RecruitingNCT07102056

First Affiliated Hospital of Zhejiang University152 enrolled

Overview

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Study Type

OBSERVATIONAL

Enrollment

152

Conditions

Neuroendocrine Tumors

Interventions

18F-AlF-NOTA-Octreotide PET-CT or PET-MRDIAGNOSTIC_TEST

18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Clinical diagnosed of neuroendocrine neoplasms. 2. Suspected of neuroendocrine neoplasms. Exclusion Criteria: 1. Inability to undergo biopsy/surgical treatment. 2. Concurrent active malignancy. 3. Severe uncontrolled comorbidities/active infections. 4. Inability to provide informed consent.

Outcomes

Primary Outcomes

Diagnostic efficacy

Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms

Time frame: through study completion, an average of 1.5 year

Central Contacts

Donghe Chen

CONTACT

0571-87236432 chendonghe@zju.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.